---
layout: default
title: Activated Charcoal Arnica Montana Root Gold Trichl
parent: 僅模型預測 (L5)
nav_order: 202
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arnica Montana Root Gold Trichl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Preparation (Activated Charcoal / Arnica / Gold Trichloride / Horse Chestnut / Lachesis Venom / Prunus Laurocerasus / Strophanthus / Tobacco): No Evaluable Repurposing Candidate Identified

---

## One-Sentence Summary

This entry consists of a complex multi-component preparation combining conventional (activated charcoal), botanical (arnica montana root, horse chestnut, prunus laurocerasus leaf), homeopathic (lachesis muta venom, gold trichloride, tobacco leaf), and cardioactive (strophanthus gratus seed) ingredients. The TxGNN model returned **no predicted indications** for this combination, and the preparation holds **no regulatory authorization in Taiwan**. There is currently insufficient structured data to support any repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this preparation, so there is no repurposing hypothesis to evaluate.

This multi-component mixture combines ingredients from very different pharmacological classes. Activated charcoal is a non-selective adsorbent used in acute poisoning management. Strophanthus gratus seed contains ouabain, a cardiac glycoside with known pharmacological activity on the Na⁺/K⁺-ATPase pump. Horse chestnut (aescin) is associated with venous insufficiency management. The remaining components — arnica montana root, lachesis muta venom, prunus laurocerasus leaf, gold trichloride, and tobacco leaf — are typically found in homeopathic or phytotherapy formulations, where the mechanistic basis is poorly characterized by conventional pharmacology standards.

Because TxGNN operates by mapping individual drug–disease relationships in a biomedical knowledge graph, a heterogeneous mixture without a unified DrugBank ID or defined mechanism of action (MOA) cannot be properly anchored in the model. The absence of any predicted indications most likely reflects this structural incompatibility rather than a genuine prediction of inefficacy.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This preparation holds no regulatory authorization in Taiwan and no NDA records were found. There is no market information to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual component risks**: While full safety data for this combination is unavailable, the presence of **strophanthus gratus seed** (ouabain source) warrants caution. Cardiac glycosides carry a narrow therapeutic index with risks including bradyarrhythmia, AV block, and digitalis toxicity. Any clinical use of preparations containing this ingredient would require cardiac monitoring. **Lachesis muta venom** (Bushmaster snake venom) as a homeopathic ingredient is prepared at high dilutions; however, source material identity should be confirmed prior to any regulatory submission.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This preparation cannot be evaluated through the standard TxGNN repurposing pipeline because it is a multi-component mixture with no unified DrugBank identifier, no defined mechanism of action, and no approved indication on record. TxGNN returned zero predicted indications, making it impossible to proceed with any repurposing assessment under the current framework.

**To proceed, the following is needed:**

- **Decompose the preparation into individual active ingredients** and evaluate each component separately through the TxGNN pipeline (e.g., ouabain from strophanthus gratus, aescin from horse chestnut)
- **Clarify the regulatory intent**: Is this a homeopathic product, a phytotherapy combination, or a conventional multi-drug formulation? The regulatory pathway differs significantly
- **Obtain DrugBank IDs** for pharmacologically active components (activated charcoal, ouabain/strophanthin, aescin) to enable knowledge-graph anchoring
- **Define original indication(s)** — without a declared therapeutic purpose, no repurposing direction can be assessed
- **Safety review of strophanthus gratus content**: Establish dose, dilution factor, and ouabain concentration before any clinical consideration
- Retrieve the TFDA package insert (if any historical registration exists) to fill DG001 and DG002 data gaps
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

